过氧化物酶体增殖活化受体γ激动剂罗格列酮对MG63细胞抑制生长及促进凋亡的作用  

Effect of peroxisome proliferator activated receptor γ agonist rosiglitazone on proliferation and apoptosis of MG63 cells

作　　者：李啸然[1] 李月白[1] 杨妍[1] 李晓坤[1] 全碧波[1] 王义生[2] 

机构地区：[1]郑州大学基础医学院生物化学与分子生物学教研室,450001 [2]郑州大学第一附属医院骨科

出　　处：《中华实验外科杂志》2011年第11期1967-1969,共3页Chinese Journal of Experimental Surgery

摘　　要：目的观察过氧化物酶体增殖活化受体γ（PPARγ）激动剂罗格列酮对骨肉瘤细胞株MG63的生长抑制及诱导凋亡作用。方法取人骨肉瘤MG63细胞，用终质量浓度为0．5、5．0、50．0、100．0μmol／L罗格列酮分别处理细胞，对照组不给予药物，噻唑蓝（MTT）比色法测定药物作用24、48、72h对细胞生长的抑制率；流式细胞术（FCM）检测终质量浓度0、0．5、5．0、50．0μmol／L罗格列酮处理24、48h细胞周期分布；TUNEL法检测终质量浓度0．5μmol／L罗格列酮处理48h的细胞凋亡，并计算凋亡指数（AI）。结果细胞生长抑制率：（1）罗格列酮各浓度作用24、48、72h，2个时间点抑制率两两比较的差异均有统计学意义（P〈0．01），有随时间增长而增加的趋势，其中0．5μmol／L对细胞的抑制率（％）分别为30．10±0．01、46．70±0．01和48．80±0．02；（2）在各时间点，各浓度组间比较差异均有统计学意义（P〈0．01），在0．5—50．0μmol／L浓度组区间，相同时间点的抑制率有随浓度升高而降低的趋势。细胞周期：（1）不同浓度的各细胞周期分布差异有统计学意义（P〈0．01）。在24、48h时间点均表现为用药组G0／G1期细胞比例高于对照组，0．5μmol／L组细胞比例最高，但随用药浓度增加，G0／G1期比例有下降趋势；用药组S期细胞比例均低于对照组，随用药浓度增加，S期比例有增高趋势；即用药可将细胞周期阻滞在G0／G1期的作用；（2）不同时间点间细胞周期分布变化的差异无统计学意义（F=0．36，P〉0．05）。细胞凋亡：0．5μmol／L组凋亡率（14．33±3．35）％明显高于对照组（2．82±0．63）％（P〈0．01），光镜下可见药物组细胞核固缩及散在的凋亡小体。结论PPARγ激动剂罗格列酮能明显抑制人骨肉瘤MG63细胞的增殖，诱导该细胞G1期阻滞和细胞凋亡。Objective To investigate the influence of peroxisome proliferator-activated receptor γ （PPARγ） agonist rosiglitazone on the growth and apoptosis of human osteosarcoma MG63 cells. Methods MG63 cells were cultured with rosiglitazone at the concentrations of 0. 5, 5.0, 50. 0, 100. 0 μmol/L respectively, and the controls were not treated. The methyl thiazol tetrazolium （MTF） method was used to detect the growth inhibition rate at 24, 48 and 72 h. Flow cytometry （FCM） was used to examine the proliferation status of the cells at 24 h and 4B h which have been treated with 0, 0. 5, 5.0, 50. 0 μmoL/L rosigltazone. TUNEL assay was used to detect apoptosis in 0. 5 μmol/L rosiglitazone group at 48 h, and apoptotic index （A1） was calculated. Results The results of MTT showed： （1） In all rosiglitazone groups at 24, 48 and 72 h respectively, there was significant difference in the inhibition rate among the groups （P 〈 0. 01）, and with the prologation of time, the inhibition rate had an increased tendency. At 24, 48 and 72 h, the inhibition rate （%） in 0. 5 μmol/L rosiglitazone group was 30. 10 ± 0. 01, 46. 70 ±0. 01 and 48.80 ±0. 02 respectively ; （2） At any time point, there was significant difference in the inhibition rate among the groups （P 〈 0. 01 ）. The inhibition rate at the same time point was decreased in a concentrationdependent manner during the range from 0. 5 to 50. 0 μmol/L. The results of FCM revealed ： （ 1 ） There was significant difference in the cell-cycle distributions among the groups （P 〈 0. 01 ）. The proportion of cells in G0/G1 phase in any rosiglitazone group was higher than in control group at 24 or 48 h, and the highest proportion was achieved in 0. 5 μmol/L group. The proportion of cells in G0/G1 phase was decreased with the increase of rosiglitazone concentrations. In all rosiglitazone groups, the proportion of cells in S phase was lower than in control group, and the proportion of cells in S phase was increased with the increase in ros

关 键 词：罗格列酮 PPARΓ 骨肉瘤 脱噬作用 

分 类 号：R285[医药卫生—中药学]